C9045 – Injection, moxetumomab pasudotox-tdfk, 0.01 mg
HCPCS Level II code · C codes: Outpatient PPS (Hospital Outpatient)
HCPCS codeC9045
- Long description
- Injection, moxetumomab pasudotox-tdfk, 0.01 mg
- Short description
- Moxetumomab pasudotox-tdfk
- Pricing indicator
53Statute- Medicare coverage
DSpecial coverage instructions apply- BETOS category
O1DChemotherapy- Cross reference
- J9313
- Added
- April 1, 2019
- Last change
- October 1, 2019 – No change
- Termination date
- September 30, 2019
Frequently asked questions
What is HCPCS code C9045?
C9045 is a HCPCS Level II code for injection, moxetumomab pasudotox-tdfk, 0.01 mg. It was discontinued on September 30, 2019.
Does Medicare cover C9045?
The HCPCS file lists coverage code D: Special coverage instructions apply. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby C codes
- C9037 – Injection, risperidone (perseris), 0.5 mg
- C9038 – Injection, mogamulizumab-kpkc, 1 mg
- C9039 – Injection, plazomicin, 5 mg
- C9040 – Injection, fremanezumab-vfrm, 1mg
- C9041 – Injection, coagulation factor xa (recombinant), inactivated (andexxa), 10 mg
- C9042 – Injection, bendamustine hcl (belrapzo), 1 mg
- C9043 – Injection, levoleucovorin, 1 mg
- C9044 – Injection, cemiplimab-rwlc, 1 mg
- C9046 – Cocaine hydrochloride nasal solution (goprelto), 1 mg
- C9047 – Injection, caplacizumab-yhdp, 1 mg
- C9048 – Dexamethasone, lacrimal ophthalmic insert, 0.1 mg
- C9049 – Injection, tagraxofusp-erzs, 10 mcg
- C9050 – Injection, emapalumab-lzsg, 1 mg
- C9051 – Injection, omadacycline, 1 mg
- C9052 – Injection, ravulizumab-cwvz, 10 mg
- C9053 – Injection, crizanlizumab-tmca, 1 mg
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.